Get the Daily Brief
Latest Biotech News
Illumina gets analyst confidence boost as customer spending outlook improves
JP Morgan upgraded Illumina to Overweight and set a $185 price target after surveying instrument and clinical customers about the sequencing competitive landscape. The analyst said Illumina’s...
10x Genomics buys Proteintech Genomics to deepen proteomics
10x Genomics said it acquired Proteintech Genomics to expand proteomics capabilities and strengthen multiomics workflows. The companies did not disclose the acquisition price. The move is aimed at...
Geneoscopy and Labcorp coverage tie-in underscores diagnostics reimbursement momentum
Geneoscopy said the updated CMS coverage determination for colorectal cancer screening provides a pathway that supports future RNA-based stool assays. The company positioned the decision as a...
10x and proteomics market integration continues to accelerate
10x Genomics said it will extend proteomics capabilities through its acquisition of Proteintech Genomics. The company characterized the purchase as strengthening its roadmap for integrated...
Sanofi ends late-stage nerve disease program after efficacy concern
Sanofi said it will stop a Phase 3 trial of riliprubart in a rare neurological disorder after an independent committee determined the study was unlikely to show sufficient efficacy. The decision...
Infectious disease: early clinical data for dual Lassa–rabies vaccine
Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health reported interim results from a Phase 1 trial of a dual vaccine targeting Lassa...
Dealmaking: J&J acquires Firefly Bio to bring degrader-antibody conjugates platform in-house
Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, gaining a platform for degrader antibody conjugates and strengthening its oncology pipeline technology base. J&J said the...
Dealmaking: GSK’s $10.6B Nuvalent purchase targets near-commercial lung cancer drugs under FDA review
GSK agreed to acquire Nuvalent for $10.6 billion in cash, a deal designed to add two near-commercial lung cancer therapies that are under FDA review. The acquisition includes ROS1 and ALK targeted...
Biotech financing: Parabilis upsized $670M IPO to back cancer pipeline
Parabilis Medicines priced an upsized IPO intended to raise $670 million, setting the company up to fund a multi-asset cancer pipeline. The clinical-stage firm offered 33.3 million shares at $20...
Degrader-antibody conjugates move from platforms to late-stage targets
Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, stepping deeper into degrader-antibody conjugates (DACs) with a KRAS-focused technology and a new linker approach aimed at more...
Big pharma closes lung-cancer M&A wave with Nuvalent
GSK moved to lock in a late-stage lung-cancer franchise by agreeing to buy Nuvalent for about $10.6 billion in cash, targeting two programs under FDA review: ROS1 inhibitor zidesamtinib and ALK...
Hematology M&A intensifies as Incyte grabs a Phase III von Willebrand candidate
Incyte agreed to acquire Vega Therapeutics for up to $2 billion, adding VGA039, a Phase III monoclonal antibody for von Willebrand disease (VWD). Vega039 is designed to modulate Protein S to...
Next weekly HIV pill inches closer after phase 3 success
Merck and Gilead reported two phase 3 trials showing efficacy for a once-weekly oral HIV regimen combining Merck’s islatravir with Gilead’s lenacapavir. The companies said both studies met primary...
Sanofi exits an autoimmune Phase 3 program early
Sanofi halted a Phase 3 autoimmune trial after an interim analysis indicated the therapy was “unlikely to provide sufficient efficacy.” The early termination eliminates a late-stage opportunity...
AI reaches clinical viability in neuro-oncology diagnostics
Researchers in Heidelberg unveiled Hetairos, an AI system designed to classify brain tumors using standard histology tissue sections, producing results in minutes rather than weeks for diagnostic...
Conglomerate deal-making continues as biotechs seek public-market cash
Parabilis’ IPO surged to $670 million, the largest listing in the biotech sector’s history, as the company formerly known as FogPharma prepares to fund clinical programs including zolucatetide....
Rare-disease regulation proposal targets authorization and market access together
The UK’s MHRA proposed pairing trial authorization with market access for very rare diseases, aiming to create a flexible approval pathway while acknowledging that reimbursement remains...
Infectious disease: dual Lassa–rabies vaccine reports early human data
University of Maryland’s Center for Vaccine Development and Global Health reported interim phase 1 data for a dual vaccine targeting both Lassa fever and rabies, combining inactivated rabies...
Genomics platform: Personalis gets CE-IVD marking for blood collection kits
Personalis received CE-IVD marking for its EDTA blood collection kit and cfDNA blood collection kit under the EU In Vitro Diagnostic Regulation, enabling marketing and sale in the region. The kits...
Major pharma M&A lifts late-stage oncology pipeline
GSK is set to expand its near-commercial oncology lineup with a $10.6 billion acquisition of Nuvalent, adding two lung cancer assets under FDA review—ROS1 inhibitor zidesamtinib and ALK blocker...